PROCEPT BioRobotics heads into the post-earnings stretch with analysts slashing price targets and the stock trading at $18.28 — down 13% over the past month and sitting well below where most of the Street was positioned just weeks ago.
The analyst reaction has been swift and broad. TD Cowen trimmed its target from $34 to $28 on August 5, while Piper Sandler cut from $35 to $25 and Evercore ISI moved from $30 to $23 — all three maintaining positive ratings but stepping back from prior conviction. William Blair went further, downgrading to Market Perform from Outperform outright. Earlier in the week, UBS assumed coverage with a Neutral at $20, a signal that fresh eyes on the name landed closer to the bear case. The consensus sits at "Hold" with 3 buys against 9 holds. The mean target of $22.73 implies roughly 24% upside from current levels, but that figure is actively compressing as desks reset expectations.
The Street debate centers on whether the Aquablation platform can recover procedure volume under new leadership. Bulls point to restructured sales initiatives and a growing urology robotics market as a path back to growth. Bears argue that rising reimbursement for prostatic artery embolization threatens to redirect patients away from Aquablation entirely, and that lower-than-expected handpiece sales already suggest the problem is structural rather than transitional. EPS momentum over both 30 and 90 days ranks in the 15th percentile — near the bottom of the universe — signaling that estimate revisions are continuing to move against the bulls. The short score of 67.0, while elevated in absolute terms, has edged slightly lower over the past two weeks, easing from a peak near 68.2 on July 30.
Short positioning tells a more nuanced story than the headline level might suggest. Short interest is running at 13.7% of the free float — genuinely high — but it has drifted lower through the past week, falling nearly 0.9%, and is essentially flat over the past month. The borrow market is loose: availability is running at 162%, meaning there are roughly 1.6 shares available to borrow for every share already shorted, the most available since early July. Cost to borrow has crept up 27% on the week to 0.52%, still far below levels that would signal real squeeze pressure. Days to cover stand near 4.9 on the latest FINRA settlement data. Put another way, shorts are not covering, but new short-side conviction is not building aggressively either. Options positioning has shifted more defensive than usual — the put/call ratio is at 0.43, about 1.25 standard deviations above its 20-day average of 0.34 — but it remains well short of distress-level readings given the year's high is 1.25.
T. Rowe Price added 512,000 shares in the quarter ended June 30, lifting its stake to 6.8% of shares outstanding — the most notable institutional addition in the latest filings. BlackRock added 285,000 shares to hold 8.2%. Chicago Capital trimmed by 87,000. Director Antal Rohit Desai purchased just over $1 million worth of stock in March at roughly $24, the only material open-market buy in recent insider data. Trades since then have been small routine sells by the CFO, CTO, and Chief Legal Officer in early June at prices around $28 — levels the stock no longer trades near.
The next earnings event is scheduled for November 3, giving management roughly three months to demonstrate whether its revised sales structure is translating into procedure volumes. The August 4 print, which catalyzed today's target cuts, carries no reaction data in the history yet, but the prior available print on July 29 showed only a 0.4% single-day move — modest for a stock this volatile. What to watch between now and November is whether the procedure growth cadence and handpiece revenue trends stabilise, and whether the analyst community's near-universal target compression finds a floor around the current price or continues to move lower as quarterly data trickles in.
See the live data behind this article on ORTEX.
Open PRCT on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
